E FRINDEL
Overview
Explore the profile of E FRINDEL including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
126
Citations
349
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
BOGDEN A, Moreau J, DESCHAMPS DE PAILLETTE E, TUBIANA M, FRINDEL E, Carde P
Int J Cancer
. 1998 Apr;
76(1):38-46.
PMID: 9533760
The aim of our study was to investigate the protection afforded to the bone marrow by Goralatide (AcSDKP), an inhibitor of hemopoietic stem cell proliferation, when administered alone or in...
2.
Liozon E, Volkov L, COMTE L, Trimoreau F, Pradelles P, Bordessoule D, et al.
Br J Haematol
. 1995 Apr;
89(4):917-20.
PMID: 7772535
AcSDKP is a physiological negative regulator of cell proliferation in mammals. In Ara-C-treated mice its plasmatic concentrations decrease while the CFU-S start cycling. Infusion of AcSDKP protects these animals from...
3.
Volkov L, COMTE L, FRINDEL E, Philippe M, Praloran V
Biol Cell
. 1995 Jan;
85(2-3):223-5.
PMID: 8785523
The endogenous tetrapeptide AcSer-Asp-Lys-Pro (AcSDKP) is present in the circulation and cells of mammals. Extracellular AcSDKP is a negative regulator of cell proliferation inhibiting the S phase entry of numerous...
4.
TUBIANA M, Carde P, FRINDEL E
Radiother Oncol
. 1993 Oct;
29(1):1-17.
PMID: 8295982
Acute and chronic bone marrow toxicities are the major limiting factors in the treatment of cancer. They are related to two factors. (i) The first is a decrease in the...
5.
Liozon E, Pradelles P, Venot J, Rigaud M, Cransac M, Bordessoule D, et al.
Leukemia
. 1993 Jun;
7(6):808-12.
PMID: 8501976
One of the first known effects of the endogenous peptide N-acetyl-Ser-Asp-Lys-Pro (AcSDKP) is to inhibit entry into DNA synthesis of pluripotent haematopoietic stem cells (CFU-S) in mice. A specific anti-AcSDKP...
6.
Lavignac C, Volkov L, Masse A, Rigaud M, FRINDEL E
Leukemia
. 1992 Oct;
6(10):1045-7.
PMID: 1405758
AcSDKP is a physiological negative regulator of hematopoietic stem cell proliferation. To investigate the applicability of AcSDKP in the prevention of graft-versus-host disease, this tetrapeptide was tested in mice and...
7.
FRINDEL E, Masse A, Volkov L, Lavignac C, Rigaud M
Leukemia
. 1992 Oct;
6(10):1043-4.
PMID: 1405757
AcSDKP (inhibitor of entry into cycle of pluripotent hemopoietic stem cells) is able to decrease mixed lymphocyte reaction intensity when H-2 incompatible allogeneic spleen cells are used as stimulators. This...
8.
Aizawa S, Toyama K, Mori K, FRINDEL E
Exp Hematol
. 1992 Aug;
20(7):896-9.
PMID: 1628708
The biological activity of the tetrapeptide acetyl-N-Ser-Asp-Lys-Pro (AcSDKP) on hemopoietic cell binding to the stromal cells was studied by using a rosette formation technique that quantitatively represents the specific hemopoietic...
9.
FRINDEL E, Masse A, Pradelles P, Volkov L, Rigaud M
Leukemia
. 1992 Jun;
6(6):599-601.
PMID: 1602798
A decrease of endogenous acetyl-ser-asp-lys-pro (AcSDKP) levels in murine plasma was observed after Ara-C treatment. This decrease preceded the entry of pluripotent hemopoietic stem cells (CFU-S) into the cell cycle....
10.
Volkov L, Pradelles P, COMTE L, FRINDEL E
C R Acad Sci III
. 1992 Jan;
315(12):499-504.
PMID: 1297528
The intra and extracellular kinetics of AcSDKP levels in cell culture have been studied. A close correlation was observed between the minimal level of intracellular AcSDKP (a negative regulator of...